生物医药企业与传统制药公司之间出于各自目的,常常结成以技术开发为纽带的企业联盟,前者从后者那里得到资金,后者从前者那里得到技术。与传统的技术开发合同不同,在融资性开发合同中都会约定在技术开发完成后,生物医药企业或者制药厂中的一方有权以某种形式——通常是特许专利使用金(RoyaltyFee)——继续获得技术成果应用的利益。 For their own purposes, biopharmaceutical companies and traditional pharmaceutical companies often form business alliances that are linked by technological development, where the former receives funding from the latter and the latter derives technology from the former. Unlike traditional technology development contracts, in a financing development contract, it is agreed that after the technology development is completed, one of the biopharmaceutical companies or pharmaceutical companies has the right, in some form - usually, the RoyaltyFee - Continue to benefit from the application of technological achievements.